Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.

V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies. In a recent phase II study for patients with BRAF-V600E non-small cell lung cancer (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but...

Full description

Saved in:
Bibliographic Details
Main Authors: Monika Joshi, Shawn J Rice, Xin Liu, Bruce Miller, Chandra P Belani
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0118210&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items